

Inter- American Drug Abuse Control Commission

Multilateral Evaluation Mechanism (MEM) Results of the second year evaluation for the MEM eighth round on drug supply reduction

Luis Adrian Noble MEM Unit Chief / ES-CICAD Secretariat for Multidimensional Security (SMS)



MEM Characteristics





- Governmental and objective process
- Based on transparency, impartiality and equality
- All OAS member states evaluate and are evaluated
- All evaluations are conducted in a collectively by all MS
- No country participates in its own evaluation
- Constructive process, no sanctions



MEM Main Objectives



- Achieve full implementation of the OAS's Hemispheric Drug Strategy (HDS) and its Plan of Action
- Measure individual and collective progress of the member states
- Stimulate development of technical assistance & training programs, exchange of experiences & best practices



MEM Evaluation Reports

- Each round, the MEM produces unique national & hemispheric evaluation reports that measure counterdrug performance of MS
- Reports detail the current drug situation in each member state
- Reflect key areas for improvement in MS drug efforts
- Identify areas where assistance is needed
- > All member state evaluations are done at the same time




JAS More rights

Introduction to the 8th Round ODAS More rights for more people

- First Fifth MEM rounds included recommendations based on challenges identified in each country
- Sixth and Seventh Rounds Evaluations based on a set of standard recommendations stemming from the current Plans of Action, but the evaluation methodology was maintained from previous rounds
- Eighth round Evaluation by thematic area during the first 3 years and a comprehensive evaluation on the fourth (2021-2024):
 - Independent Technical Consultants
 - Means of verification for each priority action

MEM Key Stakeholders



OAS More rights for more people

OAS 2020 Hemispheric Drug Strategy

- Consists of "Core Principles and Critical Elements" and 2 pillars:
 - Measures related to
 <u>Demand Reduction</u>
 - Measures related to
 <u>Supply Reduction</u>

HEMISPHERIC DRUG STRATEGY 2020

DAS More rights for more people

➢ Related to the MEM:

"... is the approved OAS mechanism to monitor and evaluate members states' application of this Strategy and associated Plan of Action ..."

Plan of Action, 2021-2025



- Identifies 29 objectives and 142 priority actions
- Considers the MEM to evaluate the level of fulfillment of its objectives in each member state
- Takes into account the UNGASS 2016 operational rec(s) & the United Nations Sustainable Development Goals (SDGs) of the 2030 Agenda
- Considers cross-cutting issues, such as gender perspective and human rights



Structure of the Plan of Action, 2021-2025



Institutional Strengthening6Measures of Prevention, Treatment, and Recovery Support5Measures to Control and Counter the Illicit Cultivation, Production, Trafficking, and Distribution of Drugs, and to Address their Causes and Consequences12Research, Information, Monitoring, and Evaluation4	Thematic Area	# of objectives
Recovery Support5Measures to Control and Counter the Illicit Cultivation, Production, Trafficking, and Distribution of Drugs, and to Address their Causes and Consequences12Research, Information, Monitoring, and 	Institutional Strengthening	6
Cultivation, Production, Trafficking, and Distribution of Drugs, and to Address their Causes and Consequences12Research, Information, Monitoring, and Evaluation4		5
Evaluation 4	Cultivation, Production, Trafficking, and Distribution of Drugs, and to Address their	12
International Cooperation 2		4
	International Cooperation	2

8th Evaluation Round



Evaluated Thematic Area	Evaluation Year	# of objectives
Measures of Prevention, Treatment, and Recovery Support	2021	5
Measures to Control and Counter the Illicit Cultivation, Production, Trafficking, and Distribution of Drugs, and to Address their Causes and Consequences	2022	12
Institutional Strengthening / Research, Information, Monitoring, and Evaluation / International Cooperation	2023	12
Comprehensive Evaluation	2024	Update all

Evaluation period: starting from 2019



Subject	Objective
Illicit drug production, trafficking and distribution	1
New Psychoactive Substances (NPS's)	2
Chemical substances and pharmaceutical products	3, 4 and 5
Exchange of intelligence information	6
Money laundering	7 and 8
Illicit crops and alternative development programs	9, 10 and 11
Illicit drug trafficking in small quantities	12

Drug supply reduction thematic area – Objectives (cont.)



Measures to Control and Counter the Illicit Cultivation, Production, Trafficking, and Distribution of Drugs, and to Address their Causes and Consequences

- **Objective 1:** <u>Capacity to reduce the illicit cultivation, production, trafficking, and distribution</u> of drugs
- **Objective 2:** <u>Measures to address NPS</u> and other drugs
- **Objective 3:** Legal and institutional frameworks for the monitoring and <u>control of essential</u> <u>chemical substances and precursors</u>
- **Objective 4:** <u>Availability</u> and accessibility <u>of substances</u> subject to international control <u>for</u> <u>medical and scientific purposes</u>
- **Objective 5:** Measures to prevent diversion of controlled pharmaceutical products
- **Objective 6:** Operational and <u>intelligence gathering</u> and sharing mechanisms to detect methods used by criminal organizations
- **Objective 7:** Legislative and institutional frameworks to prevent, detect, investigate, prosecute, and <u>control money laundering</u>
- **Objective 8:** Agencies for the <u>administration and disposition of seized and/or forfeited</u> <u>assets</u>
- **Objective 9:** Programs to reduce the <u>illicit cultivation</u>, production and manufacture of drugs
- **Objective 10:** Long-term <u>alternative development programs</u>, comprehensive and sustainable alternative development programs, and preventive alternative development

Drug supply reduction thematic area – Objectives (cont.)



Measures to Control and Counter the Illicit Cultivation, Production, Trafficking, and Distribution of Drugs, and to Address their Causes and Consequences

Objective 11: Plans and programs to mitigate and reduce the <u>impact of illicit crops and drug</u> <u>production on the environment</u>

Objective 12: Effects of small-scale drug trafficking on public health, the economy, social cohesion, and citizen security

MEM national evaluation reports








A substantial number of priority actions exceeding 90% compliance, including:

- Strengthening control systems to prevent the diversion and trafficking of controlled chemical substances, pharmaceutical products, and chemical precursors used in the illicit manufacture of drugs (97%).
- Improving access to controlled substances for medical and scientific purposes (94%).
- Streamlining the process for issuing authorizations for national production of, and to import and export controlled substances for medical and scientific purposes(91%).


Additional efforts need to be made in the following areas:


 The highest rate of noncompliance refers to the control of new psychoactive substances (NPS) and synthetic drugs. In this regard, 63% of countries have not made progress toward establishing and/or strengthening early warning systems (EWS), while 72% of countries have not developed innovative regulatory approaches to enhance their national control of NPS or synthetic opioids used for nonmedical purposes.




Results – MEM Evaluation 2022 Drug supply reduction









of pharmaceutical products containing precursor substances, narcotics, or psychotropic subst. individuals and corporations authorized to handle pharmaceutical products containing precursor substances, narcotics, or psychotropic

subst.

Priority Action:

5.1

Disseminating Results of the 8th Round National Reports



- Distribute and disseminate the MEM national evaluation reports and hemispheric briefs
- Use of social networks as tools to highlight the evaluations' findings
- Carry out MEM reports promotion activities, raising awareness on the evaluation process, on a continuous basis

MEM national evaluation reports





Luis Adrian Noble

Chief of the Multilateral Evaluation Mechanism (MEM) Unit Inter-American Drug Abuse Control Commission (CICAD) Secretariat of Multidimensional Security (SMS) Organization of American States (OAS) LNoble@oas.org

